Literature DB >> 31926254

An effective seven-CpG-based signature to predict survival in renal clear cell carcinoma by integrating DNA methylation and gene expression.

Lei Xu1, Jian He1, Qihang Cai1, Menglong Li1, Xuemei Pu1, Yanzhi Guo2.   

Abstract

AIMS: Currently, using clinicopathological risk factors only is not far from effective to evaluate the risk of disease progression in renal clear cell carcinoma (KIRC) patients. Molecular biomarkers might improve risk stratification of KIRC. DNA methylation occurs the whole process of tumor development and transcriptional disorders are also one of the important characteristics of tumor. Hence, this study aims to develop an effective and independent prognostic signature for KIRC patients by Integrating DNA methylation and gene expression. MAIN
METHODS: Difference analysis was conducted on DNA methylation sites and gene expression data. The Spearman's rank correlation and univariate Cox regression analysis were used to screen out the CpG sites that related with RNAs' expression and KIRC patients' overall survival. Then, a five-CpG-based prognostic classifier was established using LASSO Cox regression method. KEY
FINDINGS: The seven-CpG-based classifier can successfully divide KIRC patients into high-risk from low-risk groups, even after adjustment for standard clinical prognostic factors, such as age, stage, gender and grade. Moreover, the seven-CpG-based signature was more effective as independent prognostic factors than the combined model of these clinical factors. Six differential mRNA genes corresponding to the seven CpG sites are all related to human cancers by functional exploration. The gene functional and pathway enrichment analysis found that genes in immune-related pathways were remarkably different in high and low-risk groups. SIGNIFICANCE: The new seven-CpG-based signature could helpfully provide insights into the underlying mechanism of KIRC and may be a powerful independent biomarker for predicting of the survival of KIRC patients.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA methylation; Gene expression profile; Kidney renal clear cell carcinoma; Overall survival; Prognostic signature

Year:  2020        PMID: 31926254     DOI: 10.1016/j.lfs.2020.117289

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Tumor DNA Methylation Profiles Enable Diagnosis, Prognosis Prediction, and Screening for Cervical Cancer.

Authors:  Jiannan Tu; Shengchi Chen; Shizhen Wu; Ting Wu; Renliang Fan; Zhixing Kuang
Journal:  Int J Gen Med       Date:  2022-06-27

2.  Identification of DNA methylation patterns and biomarkers for clear-cell renal cell carcinoma by multi-omics data analysis.

Authors:  Pengfei Liu; Weidong Tian
Journal:  PeerJ       Date:  2020-08-03       Impact factor: 2.984

3.  A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Yingkun Xu; Xiunan Li; Yuqing Han; Zilong Wang; Chenglin Han; Ningke Ruan; Jianyi Li; Xiao Yu; Qinghua Xia; Guangzhen Wu
Journal:  PPAR Res       Date:  2020-09-22       Impact factor: 4.964

4.  Novel prognostic prediction model constructed through machine learning on the basis of methylation-driven genes in kidney renal clear cell carcinoma.

Authors:  Weihao Tang; Yiling Cao; Xiaoke Ma
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

5.  The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients.

Authors:  Zicheng Wang; Jiayi Li; Peizhi Zhang; Leizuo Zhao; Bingyin Huang; Yingkun Xu; Guangzhen Wu; Qinghua Xia
Journal:  Front Genet       Date:  2022-07-12       Impact factor: 4.772

6.  The prognostic value and immunological role of the small mother against decapentaplegic proteins in kidney renal clear cell carcinoma.

Authors:  Siyue Zhang; Zhuang Liu; Mingming Xiao; Hong Liu
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.